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A hairpin ribozyme targeting the 3* LTR region (9456) of SIVmac239 was cloned into a murine retroviral vector. This target
sequence is conserved among various SIV, as well as most HIV-2, strains. The ribozyme cassette is driven from a polymerase
III promoter, that of the human tRNAval gene. Hybrid human B-/T-cell lines (CEM/174) were transduced with the retroviral
constructs and selected for G418 resistance. Cells stably expressing the 9456 ribozyme exhibited long-term resistance to
infection by a pathogenic molecular clone of SIV and two strains of HIV-2. The ribozyme was also able to effectively reduce
the proviral DNA burden. Its efficient protection against SIV/HIV-2 infection constitutes an important step toward evaluating
ribozyme gene therapy in a primate model. q 1996 Academic Press, Inc.
In addition to HIV-1, which has been clearly demon- lates. A rare exception is HIV-2 ROD, which reads
strated to be the etiological agent of AIDS (1), a second ACTTCG at the 5* end of the selected region. However,
type of human immunodeficiency virus, HIV-2, was iso- even this virus RNA should be cleaved, because the
lated from West African patients afflicted with the disease nucleotide in question is not involved in base-pairing
(2). Although genetic analysis showed 40% nucleotide with the enzyme strand and can be flexible (10).
homology between the virus types, HIV-2 isolates exhibit The retroviral vector pMJT expressing an anti-HIV-1
lower rates of transmission and a significantly longer ribozyme was constructed as described previously (11).
period of clinical latency in infected individuals in com- Single-stranded oligonucleotides containing the specifi-
parison to HIV-1 (3). HIV-2 is more closely related to cally targeting ribozyme sequence (5* GGGGATCCC-
simian immunodeficiency virus (SIV) in terms of antige- GCAGAGCAGAAGAATACCAGAGAAACACAC 3* ) and
nicity, cell tropism, and genomic organization (4). Further- one upstream of the promoter/ribozyme cassette, in the
more, both SIV and HIV-2 are able to infect, and in some LNL-6 parent vector backbone (5* CTGCTCCAAAGG-
cases produce AIDS-like symptoms, in macaque mon- GACCTCAAG 3* ), were employed to amplify a 170-bp
keys (5–7). The desperate need for an experimental ani- fragment via polymerase chain reaction (947 30 sec, 597
mal model of AIDS makes studies of HIV-2/SIV infection 30 sec, 727 30 sec; 30 cycles) from pMJT. The PCR prod-
in monkeys an obvious candidate (8). uct was subsequently digested with BamHI and MluI.
Gene therapy is a new addition to the armamentarium pMJT was digested with the same enzymes and treated
for AIDS intervention. Our group has focused on the use with alkaline phosphatase. The two fragments were then
of ribozymes, RNA molecules that contain both antisense ligated to generate the retroviral vector p9456t.
sequences and RNA-cleaving enzymatic activity. Ribo-
The amphotropic packaging cell line PA317 was
zymes are able to target the HIV replication cycle during
transfected with 20 mg p9456t DNA via the calcium phos-
its early and late phases by cleaving incoming virion RNA
phate method (12). The culture supernatant was har-
and transcribed genomic/subgenomic mRNA (9).
vested for virus 48 to 56 hr later and filtered (0.45 mm).This study focuses on the protection against viral infec-
CEM/174 cells (1 1 106) were resuspended in 5–10 mltion afforded by the use of a hairpin ribozyme targeting
of the supernatant supplemented with 10–20 ml 4 mg/a genome sequence in SIV/HIV-2. This sequence (ATT-
ml polybrene and incubated 2–4 hr at 377. Selection forCAGTCGCTCTGCG) at the 3* end of the viral mRNA is
G418 resistance (at a concentration of 400–600 mg/ml)highly conserved among known SIVmac and HIV-2 iso-
was begun 3–4 days later and continued over a period
of approximately 4 weeks. Expression of the ribozyme in
these cells was verified via a two-step process combin-1 To whom correspondence and reprint requests should be ad-
dressed. ing RT–PCR with Southern blotting (12) (data not shown).
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mately 1 1 106 cells/ml via splitting upon regular inter-
vals.The CEM/174 cells stably expressing the 9456 ribo-
zyme showed 100% protection against infection with the
pathogenic molecular clone of SIVmac239 for up to 43 days.
Figure 1B shows that despite an input virus m.o.i. of 0.02,
further SIV replication was effectively inhibited in p9456t,
as measured in terms of the levels of p26 viral core
antigen. In contrast, untransduced cells (data not shown)
and cells stably expressing pMJT both reached a peak
level of virus (80 ng/ml) by Day 15 and died off just 5
days later, as is depicted by the end of the curve. Figure
1A shows that the 9456 ribozyme also confers long-term
resistance to HIV-2 NIHZ and ISY infection.
The proviral DNA burden in ribozyme- and control vec-
tor-transduced cells was also examined. CEM/174 cells
(1 1 105) stably expressing p9456t were infected with 1
ml DNase-treated infectious virus stock in triplicate and
harvested (8 min centrifugation at 1500 rpm and transfer
of pellet to 0807) at 48 hr postinfection. This pellet was
thawed out and resuspended in 50 ml each lysis buffer
for a 60-min incubation at 567 (13). The Proteinase K
was inactivated via 10 min boiling, and the lysate was
subsequently subjected to PCR (947 45 sec, 557 45 sec,
727 30 sec; 30 cycles) with the primer pair 5* EHO (AGT-
CTCATAGCCAACATTGA) and 3* EHO (CAAAGCCAA-
TTGGTGTTATC). Two microliters of this PCR product was
subjected to a new round of five cycles (same conditions)
PCR and loaded onto a 3% agarose gel for detection.
Figure 2A shows that at 48 hr postinfection, there is aFIG. 1. (A) Inhibition of HIV-2 p26 production. Untransduced CEM/174
cells (h), cells stably expressing pMJT (s), and cells stably expressing marked difference in the intensity of the amplified 120-
p9456t were infected with HIV-2 KR (j) and HIV-2NIHZ (m) stocks at bp band between the untransduced cells (lanes 1 and
an input m.o.i. of 0.02. Viral infectivity was monitored for 37 days, the
4), those cells stably expressing the MJT ribozyme (laneduration of the experiment, via regular sampling of the culture superna-
3), and those stably transduced with p9456t (lane 2). Thetant for subsequent HIV-2 antigen capture test (Coulter). (B) Inhibition
presence of the 9456 ribozyme resulted in a significantof SIV p26 production. Untransduced CEM/174 cells (s), cells stably
expressing pMJT (L), and cells stably expressing p9456t (j) were decrease in proviral DNA (Fig. 2B). This dramatic reduc-
infected with an SIVmac239 stock at an input m.o.i. of 0.02. Viral infectivity tion may in part be due to the ability of the 9456 ribozyme
was monitored as in (A) for 43 days.
to cleave incoming viral RNA (12).
We have previously demonstrated the efficacy of anti-
HIV ribozymes in protecting T-cell lines (12), as well asStable expression of the ribozyme in the transduced
CEM/174 cells did not induce any cellular toxicity, since primary T cells (14) against diverse HIV-1 strains. Further-
more, CD34 cells transduced with the ribozyme vectorcomparable growth rates were observed among untrans-
duced, 9456 vector-transduced, and MJT vector-trans- differentiated into macrophages that were resistant to
HIV-1 infection (15). Although a pilot clinical study toduced cell lines (data not shown). The stably transduced
cells also remained morphologically indistinguishable evaluate the safety and feasibility of this approach has
been approved, initiation of such a study has been de-from the untransduced cells.
CEM/174 cells (3–5 1 105) stably expressing p9456t layed due to the various regulatory processes required
for human trials. In the meantime, the SIV/HIV-2 (ma-were challenged with two HIV-2 strains, NIHZ and ISY
(Fig. 1A), or the pathogenic, molecularly cloned virus, caque) model may serve as the most relevant animal
model.SIVmac239 (Fig. 1B). Virus supernatant was added at an
input m.o.i. of 0.02. Untransduced CEM/174 cells and In this study, a ribozyme containing a target sequence,
9456, conserved in almost all known HIV-2 (HIV-2 RODcells stably expressing pMJT were subjected to similar
challenge conditions as controls. The culture superna- is an exception), as well as numerous SIV, strains and
chosen according to a previously determined algorithmtants were sampled every 2 to 3 days beginning 3 days
postinfection for p26 antigen capture ELISA. The infected was cloned into a retroviral vector for delivery into lym-
phocytes. This target sequence is present toward the 3*cells were maintained at a concentration of approxi-
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the ability to evaluate the in vivo development of muta-
tions or the effect of specifically designed mutations. It
also allows the standardization of infection conditions,
including the level of input virus, thus minimizing the
variability that is inevitable in human trials and access
to lymphoid and/or autopsy tissues. Specific issues that
can be addressed in the SIVmac model for the adoptive
transfer of gene-altered T cells include information on
the longevity and trafficking of these cells. The effect of
different ex vivo culture and transduction conditions on in
vivo properties and that of different vectors on selectable
markers (such as CTL response to the neomycin resis-
tance gene) can also be studied. The animal data gath-
ered can then be directly applied to humans, as the same
ribozyme construct can be utilized for HIV-2 infection.
There remains a host of basic, unanswered questions
regarding the potential efficacy of gene therapy that can
be more readily addressed in an animal model. Such
issues include the optimization of gene transfer into he-
FIG. 2. (A) Effect of the stable expression of the 9456 ribozyme on
matopoietic stem cells, the maintenance of long-termproviral synthesis. Lane M represents the marker dye, which allowed
gene expression in vivo, and the evaluation of potentialus to estimate the size of our specific band; lane 1, virus present in
untransduced cells; lane 2, virus present in cells transduced with toxicity of genes expressed in multiple hematopoietic
p9456t; lane 3, virus present in cells transduced with pMJT; lane 4, as lineages. Autologous bone marrow transplants in nonhu-
in lane 1, virus present in untransduced cells. (B) Quantification of man primates using genetically marked cells have been
differences between band intensities via calculation of rato of densities
performed by several groups, and the availability of ourof PCR products.
SIV-specific ribozyme should pave the way for the under-
taking of studies of stem cell therapy for AIDS in the
SIVmac model. Recently, successful induction of rhesusend of the viral mRNA, downstream of the nef gene, and
therefore contained in spliced and unspliced mRNAs, monkey CD34/ cells to differentiate into mature T cells
in vitro has been shown (P. Johnson, unpublished data).including genomic RNA. Stable transduction of the hybrid
B-/T-cell line, CEM/174, with the ribozyme construct re- We have initiated experiments to transduce macaque
CD34/ cells with retroviral vectors expressing the 9456sulted in G418-resistant cells that did not differ from un-
transduced cells in terms of growth or viability. Upon ribozyme, so that we can examine if the macrophage, as
well as T-cell, progeny of the transduced cells would beestablishment of stable expression of the ribozyme gene,
the selected cells were challenged with a pathogenic protected against virus challenge.
molecular clone of SIVmac239 as well as two different infec-
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